Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin


HOUSTON, April 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the U.S. Food and Drug Administration ("FDA") has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia ("AML").

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the treatment of highly resistant cancers. (PRNewsfoto/Moleculin Biotech, Inc.)

"We are thrilled that Annamycin has been granted Fast Track Designation," commented Walter Klemp, Moleculin's Chairman and CEO. "Not only does this make us eligible for accelerated approval and priority review, but it serves as an important validation of the significant unmet need we are trying to address. Currently, Annamycin is in separate Phase I/II trials in the U.S. and Europe for the treatment of AML and the Company has recently announced positive interim top line data."

A drug that receives Fast Track designation is eligible for some or all of the following:

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and AML, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin Biotech is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.

For more information about the Company, please visit http://www.moleculin.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Annamycin to benefit from an accelerated approval pathway or ultimate approval from the FDA for Annamycin. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.  Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts
Joe Dorame
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com

 

SOURCE Moleculin Biotech, Inc.


These press releases may also interest you

at 10:39
Among a select group of facilities world-wide, CareOne's LTACH at Trinitas Regional Medical Center has been recognized and named a Passy-Muir Center for Excellence.  Through the Centers of Excellence Program, Passy-Muir, Inc. recognized health care...

at 10:37
IHRC, Inc. senior scientific advisor Dr. Stephen A. Morse uses his expertise in microbiology and public health to further the development of the field of microbial forensics, a valuable asset in the fight against bioterrorism as well as for tracing...

at 10:35
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced that Daniel Florin has joined its Board of Directors. Mr. Florin has been serving as...

at 10:34
Elsevier, a global leader in information analytics, specializing in science and health, is making clinical review articles and book chapters on rare and undiagnosed diseases free for 60 days beginning on Rare Disease Day (#RareDiseaseDay), February...

at 10:26
The American Association of Endodontists (AAE) - representing the dental specialists who save your natural teeth - is launching today the second "Worth Saving" Landmarks Contest. This is your chance to vote (aae.org/landmarks) for your favorite of...

at 10:15
IPC, LLC DBA PlatinumCode announces they have been awarded a three-year agreement for Vizient, Inc., the largest member-driven health care performance improvement company in the country. Effective March 1, 2020, Vizient members will have access to...



News published on 18 april 2019 at 07:30 and distributed by: